Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06727604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 134 sitesv28
  2. Site details revised at 1 of 134 sitesv27
  3. Re-verified, no change to tracked fieldsv26
  4. Study sites: 133 to 134v25
  5. Trial sites expanded: 130 → 133 locationsv24
  6. Re-verified, no change to tracked fieldsv23
  7. Trial sites expanded: 125 → 130 locationsv22
  8. Study sites: 121 to 125v21
  9. Study sites: 115 to 121v20
  10. Study sites: 112 to 115v19
  11. Study sites: 101 to 112v18
  12. Study sites: 100 to 101v17
  13. Re-verified, no change to tracked fieldsv16
  14. Study sites: 92 to 100
    • Eligibility criteria shortened, about 217 words
    v15
  15. Study sites: 91 to 92v14
  16. Study sites: 78 to 91v13
  17. Study sites: 75 to 78v12
  18. Study sites: 69 to 75v11
  19. Study sites: 43 to 69v10
  20. Study sites: 28 to 43v9
  21. Study sites: 26 to 28v8
  22. Study sites: 20 to 26v7
  23. Eligibility criteria revisedv6
  24. Study sites: 14 to 20v5
  25. Study sites: 6 to 14v4
  26. Study sites: 1 to 6v3
  27. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2024 to Dec 17, 2024
    v2
  28. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Trial Details
NCT Number NCT06727604
Lead Sponsor Immunovant Sciences GmbH
Conditions
(from sponsor)		 Graves' Disease
Related terms Graves Disease, Hyperthyroidism
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov